A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme

ConditionStem Cell Transplantation

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age7-12

SponsorHu Peng

About this trial

Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.

Eligibility criteria

Qualifiers

Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;

Age between 7-12 years old, male or female not limited; Weight<40kg

The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia;

There are HLA matched or mismatched donors who meet the donor criteria through physical examination;

Disqualifiers

Psychiatric patients;

Participants in clinical trials of other drugs within the past month;

There are no suitable HLA mismatched donors available.

Other researchers have determined that they are not suitable to participate in this study.

Trial design

Treatments tested in this trial

Supergraft

Treatment groups

5 Participants

are divided into 1 treatment group

Sponsors and collaborators

Hu Peng

Lead sponsor

The First People's Hospital of Yunnan

Sponsor institution

Source ClinicalTrials.gov